Cystic Fibrosis - Disease Modifiers: Who? What? Why? How? When?

In 2019 the NHS agreed to fund treatment with two new disease modifying drugs in Cystic Fibrosis (Orkambi® and Symkevi®)

During this session we will examine:

• What access to these treatments means for people with Cystic Fibrosis?
• What they do and how they are used in practice?
• What specialist and generalist pharmacists need to know about these drugs?

We will support this by revising the underlying disease processes in Cystic Fibrosis and how we provide best pharmaceutical care for people with Cystic Fibrosis

We will consider the future of medicines use in Cystic Fibrosis and how the role of the CF pharmacist will develop over the next five years.

Patrick has been Assistant Head of Pharmacy at Nottingham University Hospitals and Clinical Services Lead since August 2017. He is also a long-standing member of the UKCPA Respiratory Group steering committee and current Chair of the UK Cystic Fibrosis Pharmacists Group (UKCFPG). Before moving to lead the clinical service he worked as the NHS England and CCG funded, embedded High Cost Drugs Pharmacist at NUH. He moved to work at NUH after over 8 years working at University Hospitals Leicester as a specialist pharmacist in Respiratory Medicine and Adult Cystic Fibrosis. He is passionate about delivering a high quality pharmacy service and the importance of knowledgeable and empathic pharmacy staff supporting people with long term conditions in getting the most out of their prescribed treatments.